Navarro-González JF, Arenas MD, Henríquez-Palop F, et al. - Researchers undertook this retrospective multicentre study to report data on the use, efficacy as well as safety of sucroferric oxyhydroxide (SO) in real clinical practice. This analysis involved 220 patients from 11 Spanish centres. In 70% of participants, SO was started because of inadequate control of serum phosphate (P), and 24.5% received it to decrease the number of tablets. An increase in monotherapy with SO, from 44% to 74.1%, was noted, with a decrease in the average daily number of sachets/tablets from six to two. A reduction in serum P by 20% was detected, with a significant decline in intact parathyroid hormone concentrations. Overall, findings revealed that better control of serum P, a decrease in the number of tablets and an improvement in therapeutic adherence all were conferred by SO when used in real-life settings. Benefits may be provided by SO with regards to secondary hyperparathyroidism and nutritional status.